- FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trialIn its first meeting in about nine months, the FDA’s advisory committee of oncology experts voted 6-3 Thursday that a late-stage trial for AstraZeneca’s oral SERD camizestrant didn't show a “clinic…Endpoints · 2mo ago↗ source
- Krazati fails confirmatory trial in colorectal cancer, putting approval at riskBristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated…Endpoints · 2mo ago↗ source
- House panel calls to ban China data from FDA drug trial applicationsA powerful spending committee in Congress wants the FDA to ban the use of clinical trial data from China in future applications by drugmakers to test new treatments. The language was